Compounds > 8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine
Page last updated: 2024-09-04

8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine and tg 003

8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine has been researched along with tg 003 in 1 studies

Compound Research Comparison

Studies
(8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine)		Trials
(8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine)		Recent Studies (post-2010)
(8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine)		Studies
(tg 003)		Trials
(tg 003)		Recent Studies (post-2010) (tg 003)
2801245033

Protein Interaction Comparison

ProteinTaxonomy8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine (IC50)tg 003 (IC50)
Dual specificity protein kinase CLK2Mus musculus (house mouse)0.2
Dual specificity protein kinase CLK4Mus musculus (house mouse)0.015
Dual specificity protein kinase CLK1Mus musculus (house mouse)0.02
Dual specificity protein kinase CLK1Homo sapiens (human)0.064
Dual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)0.6172
Dual specificity tyrosine-phosphorylation-regulated kinase 1AMus musculus (house mouse)0.012

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J1

Other Studies

1 other study(ies) available for 8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine and tg 003

ArticleYear
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
    Nature chemical biology, 2009, Volume: 5, Issue:10

    Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection

2009